Inovio director granted RSUs and stock options

INOVIO PHARMACEUTICALS, INC. reported a routine equity compensation grant to director David B. Weiner.

Rhea-AI Filing Summary

INOVIO PHARMACEUTICALS, INC. reported a routine equity compensation grant to director David B. Weiner. He was awarded 34,200 restricted stock units, each representing one share of common stock, and 41,800 common stock options with an exercise price of $1.23 per share. Both the RSUs and the options vest 100% on May 20, 2027, and the options expire on May 20, 2036. These awards were granted under the company’s 2023 Omnibus Incentive Plan pursuant to its non-employee director compensation policy and do not involve any open-market buying or selling of shares.

Insider Trade Summary

Grant/Award: 76,000 shares

Grant/Award 2 txns

Insider Weiner David B.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock Options	41,800	$0.00	$0.00
Grant/Award	Restricted Stock Unit	34,200	$0.00	$0.00

Holdings After Transaction: Common Stock Options — 41,800 contracts (Direct); Restricted Stock Unit — 34,200 contracts (Direct)

Footnotes (3)

1. F1. This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.
2. F2. Options to vest 100% on May 20, 2027.
3. F3. Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027.

Key Figures

RSUs granted: 34,200 units Stock options granted: 41,800 options Option exercise price: $1.23/share +3 more

6 metrics

RSUs granted 34,200 units Restricted stock units granted to director; vest 100% on May 20, 2027

Stock options granted 41,800 options Common Stock Options granted to director; vest 100% on May 20, 2027

Option exercise price $1.23/share Exercise price for 41,800 Common Stock Options granted May 20, 2026

Option expiration May 20, 2036 Expiration date for Common Stock Options granted to director

RSU post-transaction holdings 34,200 units Total restricted stock units held following the grant

Option post-transaction holdings 41,800 options Total Common Stock Options held following the grant

Key Terms

Restricted Stock Unit, 2023 Omnibus Incentive Plan, non-employee director compensation policy, Common Stock Options, +1 more

5 terms

Restricted Stock Unit financial

"Each restricted stock unit represents a contingent right to receive one share of common stock."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

2023 Omnibus Incentive Plan financial

"This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy."

non-employee director compensation policy financial

"This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy."

Common Stock Options financial

"Common Stock Options with an exercise price of $1.23 per share were granted to the director."

vest 100% financial

"These restricted stock units will vest 100% on May 20, 2027."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did INO director David B. Weiner report?

David B. Weiner reported receiving equity awards, not trading stock. He was granted 34,200 restricted stock units and 41,800 stock options as director compensation under Inovio’s 2023 Omnibus Incentive Plan.

How many RSUs did David B. Weiner receive from Inovio (INO)?

He received 34,200 restricted stock units. Each RSU represents a contingent right to receive one share of Inovio common stock, with all units scheduled to vest in full on May 20, 2027, subject to plan terms.

What are the terms of the stock options granted to INO director David B. Weiner?

Weiner was granted 41,800 common stock options with a $1.23 exercise price. These options vest 100% on May 20, 2027 and expire on May 20, 2036, aligning with Inovio’s non-employee director compensation policy.

Were there any open-market stock purchases or sales by David B. Weiner in this INO Form 4?

No open-market purchases or sales were reported. The Form 4 only shows compensation-related grants of restricted stock units and stock options, both classified as grant or award acquisitions rather than buy or sell transactions.

Under which plan were the latest INO director equity grants made?

The equity grants were made under Inovio’s 2023 Omnibus Incentive Plan. The footnotes specify that these awards follow the company’s non-employee director compensation policy, indicating routine board compensation rather than discretionary market trading.

When will David B. Weiner’s INO RSUs and options vest?

Both the 34,200 restricted stock units and the 41,800 stock options are scheduled to vest 100% on May 20, 2027. After vesting, RSUs convert into shares and options become exercisable at the stated $1.23 strike price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/21/2026 - 04:11 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weiner David B.

(Last) (First) (Middle)

660 W. GERMANTOWN PIKE

SUITE 110

(Street)

PLYMOUTH MEETING PENNSYLVANIA 19462

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INOVIO PHARMACEUTICALS, INC. [ INO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Options	$1.23	05/20/2026		A		41,800(1)		(2)	05/20/2036	Common Stock	41,800	$0	41,800	D
Restricted Stock Unit	(3)	05/20/2026		A		34,200(1)		(3)	(3)	Common Stock	34,200	$0	34,200	D

Explanation of Responses:

1. This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.

2. Options to vest 100% on May 20, 2027.

3. Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027.

Remarks:

	/s/ David B. Weiner	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)